What is better, nattokinase or aspirin?

Your doctor took you off daily aspirin, and now you are wondering whether nattokinase can take its place.

It cannot — and that is the single most useful thing to know before comparing them. In 2022, the USPSTF recommended against starting low-dose aspirin for primary prevention in adults 60 and older [8], which sent a lot of people searching for something else.

Both affect clotting. But they act on different systems, and their evidence bases are separated by roughly 112,000 trial participants [2].

Table of Contents

1. Why People Are Suddenly Comparing Nattokinase and Aspirin
2. How Each One Works: Preventing Clots vs. Breaking Them Down
3. What the Evidence Shows for Aspirin
4. What the Evidence Shows for Nattokinase
5. Comparing Nattokinase and Aspirin Side by Side
6. Who Each One Is Actually For — and Why Swapping Is Dangerous
7. Getting the Dose That Was Actually Studied
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. Why People Are Suddenly Comparing Nattokinase and Aspirin

For decades, a daily 81 mg tablet was standard advice for healthy adults over 50. That changed in 2022, when the USPSTF replaced its 2016 guidance [6], moving adults aged 40 to 59 with a 10% or greater 10-year cardiovascular risk into shared decision-making, and recommending against starting aspirin at all for adults 60 and older.

The reason was arithmetic, not ideology. Newer trials found benefit in primary prevention that was low to neutral while bleeding risk rose [7], and the balance stopped favouring routine use. In one review, a coronary calcium score of 100 or higher still identified people likely to benefit, while a score of 0 identified people more likely to be harmed [7].

What that guidance did not do is tell anyone what to take instead — and that gap is why searches comparing nattokinase and aspirin have climbed. It is a reasonable question. It just has a more complicated answer than "one of these is better."

2. How Each One Works: Preventing Clots vs. Breaking Them Down

Clotting has two halves: forming clots and clearing them. Aspirin works entirely on the first half. It irreversibly inhibits the COX-1 enzyme [11], shutting down thromboxane A2 production so platelets stop clumping together. Because platelets cannot make new COX enzyme, a single dose suppresses them for their entire 10-day lifespan.

Nattokinase works on the second half. The enzyme, isolated from fermented soybeans in 1987, cleaves fibrin directly, boosts tPA-driven plasminogen activation, and inhibits PAI-1 [5] — the brake on your body's own clot-clearing system. It does not meaningfully block platelet aggregation the way aspirin does. Our complete guide to nattokinase covers this mechanism in more depth.

This is why "which is better" misfires as a question. A useful analogy: aspirin keeps bricks from being stacked into a wall; nattokinase helps demolish walls that already exist. Both relate to walls. Neither does the other's job.

• Aspirin: platelet-directed, effect lasts ~10 days per dose, taken at 81–100 mg
• Nattokinase: fibrin-directed, dosed daily, studied at 2,000 FU per day
• Aspirin: prescription-guided for millions; nattokinase: available over the counter

3. What the Evidence Shows for Aspirin

Aspirin has the deepest outcome database of almost any cardiovascular intervention. The Antithrombotic Trialists' Collaboration pooled individual data from six primary-prevention trials covering 95,000 people and 660,000 person-years, plus 16 secondary-prevention trials covering 17,000 higher-risk people [2]. In primary prevention, aspirin produced a 12% proportional reduction in serious vascular events. In secondary prevention, the reduction was roughly one-fifth.

That secondary-prevention finding still stands. The American College of Cardiology has been explicit that low-dose aspirin remains recommended for people with established disease [10] — a prior heart attack or stroke, or a history of stenting or bypass surgery. Nothing in the 2022 update changed that.

The harms are equally well characterised, which is unusual and valuable. In the ASPREE trial of 19,114 healthy older adults, major haemorrhage occurred at 8.6 events per 1,000 person-years on aspirin versus 6.2 on placebo [9], with intracranial bleeding at 2.5 versus 1.7 — and no meaningful reduction in cardiovascular disease over 4.7 years.

4. What the Evidence Shows for Nattokinase

Nattokinase's research base is real but small, and it measures different things. The most rigorous summary, a 2023 systematic review in Reviews in Cardiovascular Medicine, pooled 6 randomised trials and 546 participants [3], finding systolic blood pressure fell by 3.45 mmHg and diastolic by 2.32 mmHg versus placebo, with no notable adverse events reported.

That same review also found two results that cut the other way, and they belong in any honest summary: nattokinase was associated with a small but statistically significant rise in blood glucose, and at higher total dosages with higher total cholesterol than placebo [3]. Neither finding is large, and neither has been replicated in a dedicated trial — but "no notable adverse events" is not the whole picture.

The single most-cited positive trial randomised 86 adults with untreated systolic pressure between 130 and 159 mmHg [4] to 2,000 FU daily or placebo for 8 weeks. Net changes were −5.55 mmHg systolic and −2.84 mmHg diastolic. Modest, but reproducible across populations, which is what gives small numbers weight.

Honesty requires the other half. The largest and longest trial, NAPS, randomised 265 adults with a median age of 65.3 to 2,000 FU or placebo for 3 years [1] and found no difference in carotid intima-media thickness or arterial stiffness. At the exact dose most supplements sell, the best-designed study did not show a slowing of arterial disease — a distinction we unpack further in our article on whether nattokinase can clean arteries.

5. Comparing Nattokinase and Aspirin Side by Side

Set out plainly, the difference is not one of degree. It is a difference in what has been measured.

• Mechanism: Aspirin inhibits platelet COX-1 for ~10 days per dose [11]. Nattokinase promotes fibrinolysis via tPA and PAI-1 pathways, dosed daily at 2,000 FU [5].
• Endpoints studied: Aspirin — heart attack, stroke, vascular death [2]. Nattokinase — blood pressure, fibrinogen, clot-lysis markers, carotid imaging [3].
• Scale: Aspirin — over 112,000 participants in pooled trial data [2]. Nattokinase — 546 in the pooled meta-analysis [3], 265 in its largest single trial [1].
• Best available outcome result: Aspirin — ~20% fewer serious vascular events in secondary prevention [2]. Nattokinase — a null result on carotid thickness over 3 years [1].

There has never been a head-to-head randomised trial of nattokinase against aspirin on clinical outcomes. Not one. Any source telling you which "wins" is extrapolating past the data, and a 3.45 mmHg blood pressure change and a 20% reduction in heart attacks are not the same currency.

What is fair to say: nattokinase is a reasonable option for someone with no prescription to abandon who wants modest blood pressure and blood-flow support, with a favourable tolerability record across the 546 pooled participants. What is not fair to say is that it replaces a drug proven on hard endpoints.

6. Who Each One Is Actually For — and Why Swapping Is Dangerous

If you have had a heart attack, stroke, stent, or bypass, aspirin is secondary prevention and the ACC continues to recommend it [10]. Nattokinase is not an alternative in that setting, and no trial has tested it there.

If you are 60 or older with no cardiovascular history and were advised not to start aspirin, you are in a different position entirely — you have no prescription to stop. That is the group where a daily 2,000 FU enzyme supplement is a defensible addition to blood pressure management, diet, and exercise, on the strength of a 3.45 mmHg average reduction [3].

The substitution risk is documented, not theoretical. A natural products monograph records mechanical aortic valve thrombosis in a patient who replaced warfarin with nattokinase [12]. It also records a single case of acute cerebellar haemorrhage in a woman with a history of ischaemic stroke who was already taking daily aspirin when she started nattokinase — the monograph notes that causality could not be established given her history [12]. Health Canada also flagged in 2012 that removing vitamin K2 from supplements could theoretically raise bleeding risk, since the K2 in natto food partly offsets the enzyme's effect [12]. If you take any anticoagulant or antiplatelet drug, talk to your physician before adding nattokinase — our companion article on nattokinase as a natural blood thinner covers those interactions in detail.

7. Getting the Dose That Was Actually Studied

If you decide nattokinase fits your situation, one detail matters more than brand: potency. Nearly all the human research — the 8-week blood pressure trial [4], the 3-year NAPS trial [1], the pooled meta-analysis [3] — used 2,000 fibrinolytic units per day. A product delivering less is not the product that was tested. Our guide to how much nattokinase to take per day explains why FU matters more than milligrams.

BioAbsorb Nattokinase Enzyme delivers 100 mg at 2,000 FU per capsule — the clinically studied dose, taken once daily on an empty stomach. It uses DRcaps delayed-release vegetarian capsules, which shield the enzyme from stomach acid without the phthalates and plasticizers found in conventional enteric coatings, so it reaches the small intestine intact.

Two other choices are deliberate. The formula is vitamin K2-free, which matters for anyone already supplementing K2 or watching total intake. And every batch is third-party tested for nattokinase activity, heavy metals, gluten, and microbial contaminants, manufactured in a Canadian GMP-certified facility. Choosing the 180-capsule size works out to roughly $0.28 per day at $49.87 — a six-month supply, which is a sensible horizon given that the blood pressure trials ran 8 weeks or longer before measuring change.

Frequently Asked Questions

Can I stop taking aspirin and switch to nattokinase?

Not without your doctor's involvement, and not at all if the aspirin was prescribed after a cardiac event. Stopping aspirin in secondary prevention removes a roughly one-fifth reduction in serious vascular events [2] and replaces it with something never tested for that purpose.

Is nattokinase safer than aspirin?

It has a cleaner record in the trials conducted so far — the pooled analysis of 546 participants [3] reported no notable adverse events, though it did record small increases in blood glucose and total cholesterol. Those trials were also small and short, and they systematically excluded people on anticoagulants, so "fewer reported harms" partly reflects less exposure rather than proven safety.

Can I take nattokinase and aspirin together?

Only with medical supervision. Both influence clotting through different routes, and the one published case of intracranial bleeding on the combination involved a woman already at elevated risk from a prior ischaemic stroke, with causality never established [12]. The combination has never been studied in a randomised trial.

Does nattokinase lower blood pressure as much as medication?

No. The pooled average is a 3.45 mmHg systolic reduction [3], while most first-line antihypertensives produce considerably larger drops. It may be a useful contribution alongside other measures, not a replacement for prescribed treatment.

Why did the largest nattokinase trial fail?

NAPS measured whether 2,000 FU daily slowed arterial wall thickening over 3 years in 265 healthy adults [1], and found no difference from placebo. That is a different question from whether nattokinase affects fibrin or blood pressure — clearing plaque and clearing clots are separate processes.

Who should avoid nattokinase entirely?

Anyone taking warfarin, a direct oral anticoagulant, or antiplatelet therapy without physician oversight; anyone with a bleeding disorder, recent haemorrhagic stroke, or a mechanical heart valve; anyone scheduled for surgery within 2 weeks; and anyone pregnant or nursing, where safety data are absent [12].

Conclusion

Nattokinase and aspirin are not competitors — one blocks platelets with 112,000 participants' worth of outcome data behind it, the other supports fibrinolysis with 546. The honest answer to "which is better" is that the question assumes an equivalence the evidence does not support, and the right choice depends entirely on whether you have cardiovascular disease already. If you are exploring enzyme support with no prescription in play, start at the studied 2,000 FU dose and bring your doctor into the decision.

Research References

1. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78(4) (2021). Three-year double-blind RCT of 265 adults at 2,000 FU/day found no effect on carotid intima-media thickness or arterial stiffness versus placebo — the basis for this article's caution about nattokinase as an arterial intervention.
2. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet, Vol. 373 (2009). Antithrombotic Trialists' Collaboration pooling of 6 primary and 16 secondary prevention trials; source of the 12% and roughly one-fifth event reductions cited throughout.
3. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24(8) (2023). Pooled 6 RCTs and 546 participants; source of the 3.45 mmHg systolic and 2.32 mmHg diastolic reductions, the tolerability finding, and the blood glucose and total cholesterol increases.
4. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31(8) (2008). Eight-week trial in 86 adults with untreated systolic pressure of 130–159 mmHg; source of the −5.55 mmHg systolic and −2.84 mmHg diastolic net changes.
5. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker Insights, Vol. 13 (2018). Pharmacology review describing direct fibrin cleavage, tPA enhancement, and PAI-1 inhibition — the mechanistic basis for distinguishing nattokinase from antiplatelet drugs.
6. Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say? Cleveland Clinic Journal of Medicine, Vol. 90(5) (2023). Explains how the 2022 statement replaced the 2016 guidance and how clinicians apply 10-year risk thresholds in practice.
7. Contemporary use of coronary artery calcium for the allocation of aspirin in light of the 2022 USPSTF guideline recommendations. American Journal of Preventive Cardiology, Vol. 12 (2022). Reviews the low-to-neutral benefit and increased bleeding findings behind the guideline change, and the CAC ≥100 versus CAC = 0 risk stratification cited in Section 1.
8. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication — Recommendation Statement. US Preventive Services Task Force (2022). Primary source for the recommendation against initiating aspirin in adults 60+ and shared decision-making for ages 40–59.
9. Aspirin in Reducing Events in the Elderly (ASPREE) — trial summary. American College of Cardiology (2018). Source of the major haemorrhage rate of 8.6 versus 6.2 events per 1,000 person-years and intracranial bleeding rates in 19,114 healthy older adults.
10. New USPSTF Recommendation on Aspirin in CVD: No For Primary Prevention, Yes For Secondary Prevention. American College of Cardiology (2022). Confirms aspirin's continued role in secondary prevention for patients with established ASCVD.
11. Salicylic Acid (Aspirin). StatPearls, NCBI Bookshelf. Source for aspirin's irreversible COX-1 inhibition and the persistence of platelet suppression across the platelet lifespan.
12. Nattokinase Uses, Benefits & Dosage — Natural Products Monograph. Drugs.com. Source for the documented mechanical valve thrombosis case, the single cerebellar haemorrhage case report and its causality caveat, contraindications, and Health Canada's 2012 concern regarding vitamin K2 removal.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.